Drug intelligence / Profile preview

BNG-1 Powder

Development stage
Phase 3
Lead developer
Chang Gung Memorial Hospital
Administration
Oral
01

Overview

**BNG-1 Powder** is a Taiwan-approved, orally administered multi-herb traditional Chinese medicine formula developed for adjunctive treatment of ischemic stroke in adults younger than 65 years who are already receiving aspirin. The prescription product contains eight botanical ingredients: Angelica sinensis root, Astragalus root, bamboo silica, Bupleurum root, Coptis rhizome, Glycyrrhiza root, ginseng root, and Scutellaria root. Preclinical work describes broad phosphodiesterase inhibition, particularly PDE1 and PDE7A1, with proposed antiplatelet, anti-inflammatory, neuroprotective, and cerebral-hemodynamic effects. In a randomized clinical study in acute ischemic stroke, BNG-1 plus aspirin was well tolerated but did not demonstrate a statistically significant efficacy difference versus placebo plus aspirin in the reported 42-patient phase 2 analysis. ([service.mohw.gov.tw](https://service.mohw.gov.tw/DOCMAP/CusSite/TCMLResultDetail.aspx?LICENUM=060064&LICEWORDID=01))

Brand names
BNG-1 PowderBNG1 PowderBNG 1 Powder腦得生養腦散
02

Targets

PDE1 (Phosphodiesterase 1)PDE7A (Phosphodiesterase 7A)

Beyond the preview

Go deeper on BNG-1 Powder.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNG-1 Powder.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call